Literature DB >> 28130852

A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection.

M-Y Zhu1, X Zou2, Q Li3, D-M Yu1, Z-T Yang4, D Huang1, J Chen1, Q-M Gong1, D-H Zhang1, Y Zhang2,5, L Chen3, P-Z Chen6, X-X Zhang1,6.   

Abstract

Several noninvasive blood biomarkers have been established for the assessment of liver fibrosis in patients with chronic hepatitis B virus (HBV) infection, but their clinical performance remains inconclusive. Here, we compared the diagnostic performance of these biomarkers and developed a novel algorithm for assessing liver fibrosis. Six hundred and sixteen chronically HBV-infected and treatment-naïve patients who underwent liver biopsy were enrolled and randomly divided into training (N=410) and internal validation cohorts (N=206). One hundred and fifty-nine patients from another centre were recruited as an external validation cohort. Receiver operating characteristic (ROC) curves were used to analyse the performance of the gamma-glutamyltransferase-to-platelet ratio (GPR), red cell volume distribution width-to-platelet ratio (RPR), FIB-4 index, aspartate aminotransferase-to-platelet ratio index (APRI) and HBV DNA level against liver histology, and a novel algorithm was developed using the recursive partitioning and regression tree (RPART) method. In the training cohort, the area under the ROC curve of FIB-4 was significantly higher than that of APRI (P=.038) but was comparable to those of GPR, RPR and HBV DNA; however, the performance of the biomarkers was similar among the validation cohort. The established RPR-HBV DNA algorithm performed better in the training cohort than any individual blood biomarker, and the corresponding sensitivity, specificity, positive predictive value and negative predictive value were 63%, 90%, 72% and 80%, respectively. In the internal and external validation cohorts, the performance of the algorithm in assessing liver fibrosis was also superior to that of other biomarkers. These results suggest that the established RPR-HBV DNA algorithm might improve the diagnostic accuracy of liver fibrosis in treatment-naïve patients with chronic HBV infection, although additional studies are warranted to confirm these findings.
© 2017 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  blood biomarkers; chronic hepatitis B virus infection; diagnosis; liver fibrosis

Mesh:

Substances:

Year:  2017        PMID: 28130852     DOI: 10.1111/jvh.12682

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Retrospective Evaluation of Non-Invasive Assessment Based on Routine Laboratory Markers for Assessing Advanced Liver Fibrosis in Chronic Hepatitis B Patients.

Authors:  Zeyu Wang; Yonghe Zhou; Pengzhi Yu; Yonggang Liu; Mei Mei; Zhuo Bian; Wei Shao; Jinxia Lv; Xin Li; Wei Lu; Liang Xu
Journal:  Int J Gen Med       Date:  2022-05-25

2.  Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China.

Authors:  Rui Huang; Guiyang Wang; Chen Tian; Yong Liu; Bei Jia; Jian Wang; Yue Yang; Yang Li; Zhenhua Sun; Xiaomin Yan; Juan Xia; Yali Xiong; Peixin Song; Zhaoping Zhang; Weimao Ding; Chao Wu
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

3.  Late presentation of chronic viral hepatitis for medical care: a consensus definition.

Authors:  Stefan Mauss; Stanislas Pol; Maria Buti; Erika Duffell; Charles Gore; Jeffrey V Lazarus; Hilje Logtenberg-van der Grient; Jens Lundgren; Antons Mozalevskis; Dorthe Raben; Eberhard Schatz; Stefan Wiktor; Jürgen K Rockstroh
Journal:  BMC Med       Date:  2017-05-03       Impact factor: 8.775

4.  Potential circulating biomarkers of circulating chemokines CCL5, MIP-1β and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection.

Authors:  Liangshan Hu; Yan Zhu; Jingqian Zhang; Wei Chen; Zeyong Li; Lihua Li; Liping Zhang; Donglin Cao
Journal:  BMC Infect Dis       Date:  2019-06-14       Impact factor: 3.090

5.  Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting staging liver fibrosis in chronic liver disease patients: A systematic review and meta-analysis.

Authors:  Ying Cai; Dina Liu; Jing Cui; Yu Sha; Hengyu Zhou; Ni Tang; Na Wang; Ailong Huang; Jie Xia
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

6.  Predicting Hepatitis B Virus Infection Based on Health Examination Data of Community Population.

Authors:  Ying Wang; Zhicheng Du; Wayne R Lawrence; Yun Huang; Yu Deng; Yuantao Hao
Journal:  Int J Environ Res Public Health       Date:  2019-12-02       Impact factor: 3.390

7.  Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels.

Authors:  Lingmei Wang; Jiao Li; Kai Yang; Hao Zhang; Qin Wang; Xiongwen Lv; Shihe Guan
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

8.  The Assessment of the Innovativeness of a New Medicine in Italy.

Authors:  Filomena Fortinguerra; Serena Perna; Roberto Marini; Alessandra Dell'Utri; Maurizio Trapanese; Francesco Trotta
Journal:  Front Med (Lausanne)       Date:  2021-12-08

9.  Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection.

Authors:  Li-Ting Yan; Li-Li Wang; Jia Yao; Ya-Ting Yang; Xiao-Rong Mao; Wei Yue; Yong-Wu Mao; Wei Zhou; Qing-Feng Chen; Yu Chen; Zhong-Ping Duan; Jun-Feng Li
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.